Cellectar Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 09/30/23 | FY 06/30/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $11.5M | $26.1M | $27.3M | — | — |
| Operating income | -$23.0M | -$51.8M | -$39.0M | — | — |
| Pretax income | -$21.8M | -$44.5M | -$42.8M | — | — |
| Income tax expense | — | $66,000 | -$60,000 | — | — |
| Net income | -$21.8M | -$44.6M | -$42.8M | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $13.2M | $23.3M | $9.6M | $19.0M | $5.2M |
| Current assets | $14.0M | $24.3M | $10.5M | $20.1M | $5.6M |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $6.5M |
| Current liabilities | $4.7M | $9.4M | $25.4M | $29.8M | $13.0M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $30.3M | $13.5M |
| Stockholders' equity | $8.5M | $14.3M | -$15.2M | -$28.0M | -$8.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$23.1M | -$47.6M | -$32.4M | — | — |
| Depreciation and amortization | $213,597 | $291,653 | $192,375 | — | — |
| Stock-based compensation | $2.3M | $4.3M | $2.4M | — | — |
| Capital expenditure | $5,880 | $104,195 | $864,038 | — | — |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | — | — |
| Impairments | $0 | $146,000 | $0 | — | — |
Shares outstanding 8.0M · Free float 83.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.